Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors valued at $8,715,000 (effective 2023-07-13).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors
- Value
- $8,715,000
- Effective
- 2023-07-13
Exact text from the filing
On July 13, 2023, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of (i) $8,715,000 in aggregate principal amount of the Company’s 6.0% Senior Convertible Promissory Notes due July 2028 (the “ Notes ”) and (ii) warrants, each exercisable to purchase one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”), at an exercise price of $2.61 per share (the “ Warrants ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Ernexa Therapeutics Inc. entered into Registration Rights Agreement with certain investors (effective 2023-07-13).
- Action
- entry
- Counterparty
- certain investors
- Effective
- 2023-07-13
Exact text from the filing
Pursuant to the Purchase Agreement, on July 13, 2023, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company has agreed to prepare and file a registration statement on Form S-3 with the Securities and Exchange Commission no later than 30 days following the Closing Date to register the resale of the shares of Common Stock issuable upon conversion of the Notes and the shares of Common Stock issuable upon exercise of the Warrants.
View on SEC.gov